{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:49:25Z","timestamp":1780969765797,"version":"3.54.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.dld.2016.08.122","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T21:09:45Z","timestamp":1473455385000},"page":"1391-1393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects"],"prefix":"10.1016","volume":"48","author":[{"given":"Philippe A.R.R.","family":"Pijls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennard P.L.","family":"Gilissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.08.122_bib0005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"Journal of Crohns and Colitis"},{"key":"10.1016\/j.dld.2016.08.122_bib0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/apt.12491","article-title":"Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease","volume":"38","author":"Moran","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.08.122_bib0015","first-page":"1","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis","volume":"8","author":"Bickston","year":"2014","journal-title":"Cochrane Database Systematic Reviews"},{"key":"10.1016\/j.dld.2016.08.122_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.122_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000556","article-title":"Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.dld.2016.08.122_bib0030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","article-title":"Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease","volume":"19","author":"Parikh","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.08.122_bib0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.122_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000326","article-title":"PRISMA-efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"Wang","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.dld.2016.08.122_bib0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T10:59:58Z","timestamp":1536404398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816307009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1590865816307009"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.08.122","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.08.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}